Immutep S.a.s.

Novartis Ag

Institut Gustave Roussy

Immutep

Aventis Pharma S.a.

Université Paris—sud

Inserm

Frédéric Triebel

Gerhard Johann Frey

Hwai Wen Chang

Walter A Blattler

Glenn Dranoff

Bernard Vanhove

Jennifer Marie Mataraza

Catherine Anne Sabatos-Peyton

Laurent Ferradini

Chrystelle Brignone

Catherine Gaudin

Thomas Haudebourg

Véronique Scott

Christophe Ronsin

Mathieu Angin

Chrystlle Brignone

Johann Gerhard

Sergio Roman-Ronan

Antibody molecules that specifically bind to LAG-3 and bispecific antibody molecules with a first binding specificity for LAG-3 and a second binding specificity for one of PD-1, TIM-3, CEACAM-1, CEACAM-5, PD-L1, or PD-L2, are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.

Antibody molecules to LAG-3 and uses thereof

Antibodies, or antigen-binding fragments thereof, that bind to Lymphocyte-activation gene-3 (LAG-3) are described, in particular antibodies, or antigen-binding fragments thereof, that are agonists of LAG-3. The antibodies bind to LAG-3 and inhibit antigen-induced CD4and/or CD8T cell proliferation, or antigen-induced CD4and/or CD8T cell activation. The antibodies may be used as medicaments, in particular for the treatment of conditions associated with proliferation and/or activation of CD4and/or CD8T cells, such as inflammatory and autoimmune disorders.

Anti-LAG-3 antibodies

Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.

The present disclosure relates to the use of a recombinant LAG-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an infectious disease or cancer.

Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response

The present invention relates to a peptide compound which causes a tumor-specific T response, and which comprises a sequence of at least 8 consecutive amino acids of the peptide sequence encoded by a frame-shifted sequence of the iCE gene. The invention also relates to a pharmaceutical composition comprising said peptide compound and to the use of these compounds for manufacturing a medicinal product intended for treating cancer, in particular for treating solid tumors.

Peptide compounds derived from a shifted ORF of the iCE gene

The invention concerns a method for identifying peptide compounds derived from hsp70, having at least one mutation relative to the hsp70 natural sequence, said compounds bringing about a response T specific of tumours, and the peptide compounds obtainable by said method. The invention also concerns the use of said peptide compounds for performing repeated immunization in a subject so as to interrupt immune tolerance for the corresponding natural (non-mutated) peptide. Said peptide compounds are useful for preparing a medicine designed in particular for treating cancer optionally in combination with any agent provoking tumour cell stress.

Mutated peptide compounds, derived from hsp70, useful in cancer immunotherapy

Growing community of inventors

Versailles, France

Frédéric Triebel